美國的肥胖藥物市場 是由出版商Medtech Insight在2010年12月所出版的。
這份英文市場調查報告書包含139 Pages 價格從美金4750起跳。
美國有2億成年人（成人人口的68％）被分類為體重過重或肥胖。肥胖不只是是該國醫療費高漲的重大要因、也是2型糖尿病與心臟疾病等的原因。
本報告書為美國肥胖治療藥市場的動向分析，包含產品概要、前臨床或第3相實驗階段的治療藥概要等，概述如下。
總綱
第1章 肥胖的臨床概要
第2章 現在以及新興的肥胖治療藥
- 現在的減肥藥
- 被中止的減肥藥
- 新興減肥藥
- 實驗階段的肥胖治療藥
- 前臨床開發階段的肥胖治療藥
第3章 肥胖治療藥市場
第4章 企業簡介
- Amylin Pharmaceuticals, Inc.
- Arena Pharmaceuticals, Inc.
- Emisphere Technologies, Inc.
- Genentech, Inc./Roche Group
- NeuroSearch A/S
- Norgine BV
- Novo Nordisk A/S
- Orexigen Therapeutics, Inc.
- 塩野義製藥
- 武田藥品工業
- Vivus, Inc.
- Zealand Pharma A/S
Abstract
An estimated 200 million adults in the U.S. (or a staggering 68% of the adult
population) are categorized as overweight or obese. Obesity has become a
significant contributor to rising healthcare costs in the country (total
annual healthcare costs for treating obese adults now amount to nearly $150
billion). The condition is a leading cause of type 2 diabetes, disability,
heart disease, morbidity, and mortality, resulting in nearly 112,000 deaths in
the U.S. annually.
Due to the rising obesity epidemic, the market for a safe and effective weight
loss drug is extremely compelling. A successfully commercialized weight loss
drug that proves safe and effective long-term has the potential to reach
blockbuster status and generate sales in the billions of dollars, while also
benefiting billions of people worldwide.
Valued at more than $130 million in 2009, the U.S. obesity drugs market is
expected to grow at a healthy compound annual rate of 4.0%, with sales
reaching nearly $160 million in 2014. Despite the conservatively modest 5-year
forecast, a substantial number of novel drugs, including those indicated for
type 2 diabetes, are being developed and studied for the treatment of obesity
and may reach the market over the next decade, when the market is
optimistically expected to expand exponentially. Among drugs pending FDA
approval include Contrave, which received FDA panel recommendation for
approval on December 7, 2010 and is expected to launch in the U.S. early 2011;
as well as Qnexa and Lorqess, which are still pursuing FDA approval despite
panel rejections, and may reach the market in 2011 or 2012 - if the drugs are
able to alleviate the FDA' s concerns regarding drug safety. In addition,
dozens of novel drugs are currently in Phase III clinical trials that may
prove clinically safe and effective.
This dynamic report from Medtech Insight includes analyses of products,
markets, competitors, and emerging technology and opportunities. Covered
topics in this report include existing prescription weight loss drugs and
emerging obesity drugs in preclinical or Phase I-III clinical trials including
dozens of drugs under development for diabetes/metabolic disorders that are
also being evaluated for the treatment of obesity; selected drugs being
developed for targeted cellulite/fat reduction applications are also profiled.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.
Table of Contents
EXECUTIVE SUMMARY
- i. Causes of Obesity
- a. Calorie Intake
- b. Genetics
- c. Behavior and Environment
- d. Diseases/Disorders and Drug Use
- ii. Health Risks
- iii. Statistics
- iv. Obesity Drugs Market
- a. Market Forecast
- v. Methodology
- Exhibit ES-1: Body Mass Index and Obesity
- Exhibit ES-2: Surgeon General' s Call to Action to Prevent and Decrease
Overweight and Obesity
- Exhibit ES-3: Trends in Overweight, Obesity, and Morbid Obesity,
1988-2008
- Exhibit ES-4: Trends in Overweight, Obesity, and Morbid Obesity,
1960-2008
- Exhibit ES-5: Prescription Obesity Drugs, Market Forecast, 2009-2014
1. CLINICAL OVERVIEW OF OBESITY
- 1.1 Causes of Obesity
- 1.1.1 Calorie Intake
- 1.1.2 Genetics
- 1.1.3 Behavior and Environment
- 1.1.4 Diseases/Disorders and Drug Use
- 1.2 Health Risks
- 1.2.1 Diabetes
- 1.2.2 Cancer
- 1.3 Statistics
- Exhibit 1-1: Body Mass Index and Obesity
- Exhibit 1-2: Surgeon General' s Call to Action to Prevent and Decrease
Overweight and Obesity
- Exhibit 1-3: Comorbidities of Obesity
- Exhibit 1-4: Trends in Overweight, Obesity, and Morbid Obesity,
1988-2008
- Exhibit 1-5: Trends in Overweight, Obesity, and Morbid Obesity,
1960-2008
- Exhibit 1-6: Prevalence of Obesity Among Men, by Race/Ethnicity,
1988-1994 and 2007-2008
- Exhibit 1-7: Prevalence of Obesity Among Women, by Race/Ethnicity,
1988-1994 and 2007-2008
- Exhibit 1-8: 2007, Prevalence of Obesity Among Adults, by State
2. CURRENT AND EMERGING OBESITY DRUGS
- 2.1 Current Obesity/Weight Loss Drugs
- 2.1.1 Genentech/Roche Group with GlaxoSmithKline
- 2.1.2 Teva Pharmaceuticals/Teva Pharmaceutical Industries
- 2.2 Discontinued Obesity/Weight Loss Drugs
- 2.2.1 Abbott Laboratories
- 2.2.2 Merck
- 2.2.3 Pfizer
- 2.2.4 sanofi-aventis
- 2.3 Emerging Obesity/Weight Loss Drugs
- 2.3.1 Arena Pharmaceuticals with Eisai
- 2.3.2 Orexigen Therapeutics with Takeda Pharmaceutical
- 2.3.3 Vivus
- 2.4 Selected Obesity Drugs in Clinical Trials
- 2.4.1 7TM Pharma
- 2.4.2 Amylin Pharmaceuticals with Takeda Pharmaceutical
- 2.4.3 Compellis Pharmaceuticals
- 2.4.4 Emisphere Technologies
- 2.4.5 GlaxoSmithKline
- 2.4.6 Glenmark Pharmaceuticals
- 2.4.7 GW Pharmaceuticals
- 2.4.8 Lithera
- 2.4.9 Mitsubishi Tanabe Pharma/Mitsubishi with Johnson & Johnson
- 2.4.10 NeuroSearch
- 2.4.11 Norgine with Takeda Pharmaceuticals North America/ Takeda
Pharmaceutical
- 2.4.12 Novo Nordisk
- 2.4.13 Obecure/Bio-Light
- 2.4.14 Phosphagenics with Calzada Limited
- 2.4.15 Roche Group with Ipsen
- 2.4.16 Shionogi
- 2.4.17 Transtech Pharma
- 2.4.18 Wyeth/Pfizer
- 2.4.19 Zealand Pharma with sanofi aventis
- 2.4.20 Zydus Cadila/Cadila Healthcare
- 2.5 Selected Obesity Drugs in Preclinical Development
- Exhibit 2-1: Selected Weight Loss Drugs and Their Adverse Effects, by
Decade
- Exhibit 2-2: Orlistat, Mechanism of Action
- Exhibit 2-3: 2010, Emerging Obesity/Weight Loss Drugs
- Exhibit 2-4: 2010, Selected Obesity Drugs in Clinical Trials
- Exhibit 2-5: Lorcaserin, Selected BLOOM and BLOSSOM Clinical Trial
Results
- Exhibit 2-6: SEQUEL Extension Trial, Primary Endpoints
- Exhibit 2-7: CP404, Mechanism of Action
- Exhibit 2-8: Tesofensine, Mechanism of Action
- Exhibit 2-9: 2010, Selected Obesity Drugs in Preclinical Development
3. OBESITY DRUGS MARKET
- 3.1 Market Analysis
- 3.1.1 Drugs Pending Approval
- 3.1.2 Emerging Drugs
- 3.1.3 Market Drivers
- 3.1.4 Market Limiters
- 3.2 Competitive Analysis
- Exhibit 3-1: Prescription Obesity Drugs, Market Forecast, 2009-2014
- Exhibit 3-2: Prescription Obesity Drugs, Market Forecast, by Drug,
2009-2014
- Exhibit 3-3: Selected Drugs under Development for the Treatment of
Type 2 Diabetes and Obesity
- Exhibit 3-4: 2009, Prescription Obesity Drugs Market, Share by
Supplier
4. COMPANY PROFILES
- 4.1 Amylin Pharmaceuticals, Inc.
- 4.2 Arena Pharmaceuticals, Inc.
- 4.3 Emisphere Technologies, Inc.
- 4.4 Genentech, Inc./Roche Group
- 4.5 NeuroSearch A/S
- 4.6 Norgine BV
- 4.7 Novo Nordisk A/S
- 4.8 Orexigen Therapeutics, Inc.
- 4.9 Shionogi & Co. LTD
- 4.10 Takeda Pharmaceutical Company Limited
- 4.11 Vivus, Inc.
- 4.12 Zealand Pharma A/S
|
